Evidence map›Paper›PMID 41727008›Full record

ArticlebioRxiv : the preprint server for biology2026

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy.

Thomas J Kalantzakos, Yufan Zhou, Xingyu Liu, Joshua Proehl, Cameron Durfee, Ian Tamayo, Nuri Alpay Temiz, Benjamin Troness, Anusha Soni, Harshita B Gupta and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas J KalantzakosDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Yufan ZhouDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Xingyu LiuDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Joshua ProehlDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Cameron DurfeeDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Ian TamayoDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Nuri Alpay TemizInstitute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA.
Benjamin TronessDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Anusha SoniDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Harshita B GuptaDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-9034-9112

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LUZHE SUN · 1991 to 2026
$59.1M
PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5M
Targeting innate immune pathways in breast cancers with chromosomal instabilityP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$14.5M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
CTSA Predoctoral T32 at The University of Texas Health Science Center at San AntonioT32TR004545 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Yong-Hee Patricia Chun, Christopher R. Frei · 2023 to 2026
$1.1M
Illumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600k
NCATS NIH HHS T32 TR004545NCI NIH HHS P01 CA234228NCI NIH HHS P30 CA054174NCI NIH HHS P50 CA247749NIGMS NIH HHS T32 GM113896NIGMS NIH HHS T32 GM145432NIH HHS S10 OD030311
6 · The paper itself

Abstract

Breast cancer is the most common cancer diagnosis in women. Clinical studies with triple-negative breast cancer (TNBC) are encouraging for immunotherapy combined with chemotherapy (anti-PD-1 with paclitaxel and/or carboplatin). However, additional clinical advances may be pursued more rapidly with assistance from preclinical TNBC models including syngeneic mammary tumor cell lines. Here, we report two mammary tumor cell lines that exhibit differential responsiveness to immunotherapy

Indexed as

anti-tumor immune responsescheckpoint therapyimmunotherapysyngeneic murine tumor modelstriple-negative breast cancer (TNBC)

Identifiers

PMID41727008
PMCPMC12919076

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.